X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (307) 307
oncology (259) 259
humans (251) 251
olaparib (239) 239
ovarian cancer (230) 230
olaparib maintenance therapy (204) 204
female (191) 191
poly polymerase (152) 152
cancer (142) 142
chemotherapy (123) 123
mutation (115) 115
ovarian neoplasms - drug therapy (110) 110
homologous recombination (98) 98
open-label (95) 95
breast cancer (92) 92
tumors (89) 89
parp inhibitor (85) 85
dna repair (84) 84
parp inhibitors (80) 80
ovarian neoplasms - genetics (77) 77
care and treatment (72) 72
antineoplastic agents - therapeutic use (67) 67
poly polymerase inhibitors - therapeutic use (67) 67
ovarian-cancer (65) 65
pharmacology & pharmacy (65) 65
maintenance therapy (64) 64
animals (63) 63
dna damage (59) 59
clinical trials (58) 58
double-blind (58) 58
deoxyribonucleic acid--dna (57) 57
brca (55) 55
breast-cancer (55) 55
fallopian-tube (55) 55
research (55) 55
middle aged (54) 54
brca1 protein - genetics (53) 53
monosaccharides (52) 52
sugars (52) 52
aged (50) 50
brca1 (50) 50
cancer therapies (50) 50
ovarian neoplasms - pathology (47) 47
phthalazines - therapeutic use (46) 46
piperazines - therapeutic use (46) 46
poly polymerase inhibitors - pharmacology (46) 46
adult (45) 45
brca2 protein - genetics (45) 45
repair (45) 45
health aspects (44) 44
endocrine system diseases (42) 42
genetic aspects (42) 42
medicine & public health (42) 42
obstetrics & gynecology (42) 42
pegylated liposomal doxorubicin (42) 42
patients (41) 41
poly polymerase inhibitors (40) 40
review (40) 40
synthetic lethality (40) 40
antineoplastic agents - pharmacology (38) 38
dna-repair (38) 38
parp (38) 38
recurrent epithelial ovarian (38) 38
therapy (38) 38
analysis (37) 37
carcinoma (36) 36
negative breast-cancer (36) 36
ribose (36) 36
dna-damage (35) 35
drug therapy (35) 35
inhibitors (35) 35
molecular targeted therapy (35) 35
mutations (35) 35
women (35) 35
bevacizumab (34) 34
brca1 protein (34) 34
carcinoma, ovarian epithelial (34) 34
cell line, tumor (34) 34
epithelial ovarian (34) 34
poly polymerases - metabolism (34) 34
brca2 (33) 33
platinum (33) 33
somatic mutations (33) 33
combination (32) 32
genes, brca1 (32) 32
male (32) 32
phase-i (32) 32
phthalazines - pharmacology (32) 32
piperazines - pharmacology (32) 32
apoptosis (30) 30
biomarkers (30) 30
brca mutation (30) 30
brca2 mutations (30) 30
medical research (30) 30
multicenter (30) 30
survival (30) 30
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
hematology, oncology and palliative medicine (29) 29
germ-line mutation (28) 28
polymerase (28) 28
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 12/2016, Volume 375, Issue 22, pp. 2154 - 2164
Among patients with platinum-sensitive, recurrent ovarian cancer, the use of niraparib, a PARP inhibitor, was associated with a significantly longer duration... 
TRIAL | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | MEDICINE, GENERAL & INTERNAL | SOLID TUMORS | BRCA MUTATION CARRIERS | NEGATIVE BREAST-CANCER | Humans | Middle Aged | Homologous Recombination | Antineoplastic Agents - therapeutic use | Ovarian Neoplasms - genetics | Platinum Compounds - therapeutic use | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Germ-Line Mutation | Adult | Female | Maintenance Chemotherapy | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Bone Marrow - drug effects | Double-Blind Method | Kaplan-Meier Estimate | Disease-Free Survival | Piperidines - therapeutic use | Piperidines - adverse effects | Adolescent | Aged | Indazoles - adverse effects | Neoplasm Staging | Indazoles - therapeutic use | Care and treatment | Adenosine diphosphate | Research | Diagnosis | Patients | Health aspects | Ovarian cancer | Thrombocytopenia | Adenosine | Inhibitor drugs | Toxicity | Homologous recombination | Clinical trials | Poly(ADP-ribose) polymerase | Breast cancer | Cancer therapies | Survival | Ribose | Platinum | Bone marrow | Mutation | Drug therapy | Health risk assessment | Tumors | Neutropenia | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2015, Volume 139, Issue 1, pp. 59 - 62
Abstract Purpose To determine the cost-effectiveness of olaparib, a PARP inhibitor, as maintenance therapy for platinum-sensitive (PS) recurrent ovarian... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | BRCA | PARP inhibitiors | Olaparib | Cost-effectiveness | Ovarian cancer | GYNECOLOGIC-ONCOLOGY-GROUP | STAGE-III | CHEMOTHERAPY | PACLITAXEL | OBSTETRICS & GYNECOLOGY | TRIAL | WOMEN | CISPLATIN | ONCOLOGY | Neoplasm Recurrence, Local - economics | United States | Humans | Neoplasm Recurrence, Local - drug therapy | Piperazines - economics | Phthalazines - economics | Antineoplastic Agents - therapeutic use | Models, Economic | Ovarian Neoplasms - genetics | Maintenance Chemotherapy - methods | Antineoplastic Combined Chemotherapy Protocols - economics | Genes, BRCA2 | Germ-Line Mutation | Female | Genes, BRCA1 | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Paclitaxel - economics | Decision Support Techniques | Carboplatin - administration & dosage | Piperazines - therapeutic use | Carboplatin - economics | Antineoplastic Agents - economics | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Disease-Free Survival | Poly(ADP-ribose) Polymerase Inhibitors - economics | Phthalazines - therapeutic use | Ovarian Neoplasms - economics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cost-Benefit Analysis | Maintenance Chemotherapy - economics | Neoplasm Recurrence, Local - genetics | Relapse | Cost benefit analysis | Analysis | Diseases | Index Medicus
Journal Article
Molecular Oncology, ISSN 1574-7891, 04/2018, Volume 12, Issue 4, pp. 561 - 576
A number of prostate cancer ( PC a)‐specific genomic aberrations (denominated BRCA ness genes) have been discovered implicating sensitivity to PARP inhibition... 
prostate cancer | olaparib | combination therapy | maintenance therapy | inhibition | PARP | endocrine therapy | PARP inhibition | POLY(ADP-RIBOSE) POLYMERASE | OVARIAN-CANCER | MODEL | GENE | ONCOLOGY | DNA-REPAIR DEFECTS | VELIPARIB ABT-888 | INHIBITOR | PHASE-I | s
Journal Article
Asia‐Pacific Journal of Clinical Oncology, ISSN 1743-7555, 12/2018, Volume 14, Issue 6, pp. 459 - 464
Purpose Olaparib was originally formulated as 50 mg capsules with a recommended dose of 400 mg twice daily which requires patients to take 16 capsules a day.... 
formulation | pharmacokinetics | ovarian cancer | maintenance olaparib | SEROUS OVARIAN-CANCER | ONCOLOGY | DOUBLE-BLIND | TUMORS | Index Medicus
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 05/2018, Volume 16, Issue 5S, pp. 632 - 635
In the latest NCCN Guidelines for Ovarian Cancer, the histologic subtypes of ovarian cancer are described in more depth as they vary by frequency, typical age... 
OLAPARIB | MULTICENTER | ONCOLOGY | OPEN-LABEL | PHASE-2 | CARCINOMA | MAINTENANCE THERAPY
Journal Article
JOURNAL OF THORACIC ONCOLOGY, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S704 - S705
Conference Proceeding
Cancer Research, ISSN 0008-5472, 01/2019, Volume 79, Issue 2, pp. 311 - 319
PARP inhibitors (PARPi) have shown remarkable therapeutic efficacy against BRCA1/2-mutant cancers through a synthetic lethal interaction. PARPi exert their... 
RECRUITMENT | OLAPARIB | ACTIVATION | ONCOLOGY | PATHWAY | MUTATION | MYELOID CELLS | CANCER | TUMORS | MAINTENANCE THERAPY
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2018, Volume 24, Issue 17, pp. 4062 - 4065
PARP inhibitors have transformed treatment for ovarian cancer, a cancer notable for homologous recombination (HR) deficiencies and aberrant DNA repair,... 
BRCA MUTATION | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | ONCOLOGY | PHASE-3 TRIAL | DOUBLE-BLIND | DNA-REPAIR | MAINTENANCE THERAPY
Journal Article
Annals of Oncology, ISSN 0923-7534, 04/2016, Volume 27, Issue suppl 1, pp. i40 - i44
Slow progress in improving the outcome of ovarian cancer with chemotherapy over the last decade has stimulated research into molecularly targeted therapy.... 
Olaparib | Maintenance therapy | Homologous recombination deficiency | PARP inhibitors | BRCA mutation | Ovarian cancer | Drug Synergism | Humans | Female | Mutation | Drug Discovery | Ovarian Neoplasms - drug therapy | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Index Medicus
Journal Article
Cancer discovery, ISSN 2159-8274, 02/2019, Volume 9, Issue 2, pp. 210 - 219
A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in BRCA-mutant cancers is the acquisition of BRCA reversion mutations that... 
OLAPARIB | ONCOLOGY | SECONDARY MUTATIONS | GERMLINE MUTATIONS | MAINTENANCE THERAPY | CHEMOTHERAPY | BREAST | CELL-FREE DNA
Journal Article
JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0022-2623, 05/2018, Volume 61, Issue 9, pp. 4103 - 4114
Poly(ADP-ribose) polymerase (PARP) is involved in repair of DNA breaks and is over-expressed in a wide variety of tumors, making PARP an attractive biomarker... 
CHEMISTRY, MEDICINAL | SEROUS OVARIAN-CANCER | INHIBITORS | OLAPARIB MAINTENANCE THERAPY | BLOOD-BRAIN-BARRIER | TUMORS | PET
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 09/2017, Volume 16, Issue 9, pp. 2022 - 2034
Journal Article